Adherex Technologies Inc.

Adherex Technologies Inc.

November 03, 2006 08:11 ET

Adherex to Present at Rodman & Renshaw 8th Annual Healthcare Conference

Adherex to Also Host an Analyst and Investor Meeting in New York Live Internet Webcasts for Both Meetings Will Be Available at

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - Nov. 3, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. William P. Peters, Adherex's Chairman and CEO, will be presenting at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, 2006 at 10 a.m. in the Kennedy Room of the New York Palace Hotel. The presentation will be available via live and replay Webcast at

The Company will also host an analyst and investor meeting on Wednesday, November 8, 2006, at 5 p.m. at The Westin New York at Times Square. The meeting will feature presentations on eniluracil by Dr. Robert B. Diasio, Professor, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Dr. Howard A. Burris, Director of Drug Development, Sarah Cannon Research Institute as well as presentations on ADH-1 by Dr. Douglas S. Tyler, Professor of Surgery and Chief, Section of Surgical Oncology, Duke University Medical Center and Dr. William P. Peters, Adherex's Chairman and CEO. The analyst and investor meeting will also be available via live and replay Webcast at

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications